Clinical and molecular prognostic factors associated with outcomes of first-line osimertinib in EGFR-Mutated advanced NSCLC: a systematic review and meta-analysis
Osimertinib is the standard first-line therapy for epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC), but outcomes remain heterogeneous. This meta-analysis evaluated baseline clinical and molecular prognostic factors associated with poorer outcomes in this setting. PubMed, Emba...